South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.

COVID-19 had a differing impact on Q2 consumer health sales for France's Boiron, the UK's Alliance Pharma and Sweden's Karo.

Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.